PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS

Ítems similars

• S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
  per: Matthew Heeney1, et al.
  Publicat: (2023-08-01)
• S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
  per: M Heeney, et al.
  Publicat: (2022-01-01)
• PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
  per: Miguel Abboud, et al.
  Publicat: (2023-08-01)
• Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
  per: George Joseph, et al.
  Publicat: (2020-09-01)
• S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
  per: Alan Anderson, et al.
  Publicat: (2023-08-01)